<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089283</url>
  </required_header>
  <id_info>
    <org_study_id>TASMC-10-EES-087-CTIL</org_study_id>
    <nct_id>NCT01089283</nct_id>
  </id_info>
  <brief_title>Ioflupane I123 (DaTSCAN) and Positron Emission Tomography-computed Tomography Fludeoxyglucose (PET-CT FDG) to Assess Brain Function of Parkinson Patients With Different Genetic Characteristics</brief_title>
  <official_title>I123 DAT-SCAN and PET-CT FDG to Assess Brain Function of Parkinson Patients With Different Genetic Characteristic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tel-Aviv Sourasky Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tel-Aviv Sourasky Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Parkinson disease is one of the most common neurodegenerative illnesses. The disease is
      characterized by decrease in dopamine levels and decrease in the number of dopaminergic
      neurons and dopamine receptors. There are gene mutations that increase the risk for the
      disease. Two of those mutations are on the LRRK2 gene and on GBA gene. It is yet unknown if
      there is a difference between the metabolic brain function of Parkinson patients that carry
      one of the two mutations to Parkinson patients with no known mutation.

      Participants: diagnosed Parkinson patients that carry a gene mutation in either LRRK2 or GBA
      genes, Parkinson patients with no known mutation and healthy volunteers as a control group.

      The participants will go through both examinations DAT SCAN and PET CT SCAN at the Tel Aviv
      Sourasky Medical Center Nuclear Medicine Institute.

      The examination results will be given to the participants by a doctor from the neurology
      department.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>March 2010</start_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <number_of_groups>4</number_of_groups>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Parkinson Disease</condition>
  <arm_group>
    <arm_group_label>LRRK2 mutation</arm_group_label>
    <description>Parkinson patients that carry mutation on LRRK2 gene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GBA mutation</arm_group_label>
    <description>Parkinson patients that carry mutation on GBA gene</description>
  </arm_group>
  <arm_group>
    <arm_group_label>no mutation</arm_group_label>
    <description>Parkinson patients that don't carry mutation on LRRK2 or GBA genes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy</arm_group_label>
    <description>Healthy volunteers</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Diagnosed parkinson patients ages: 40-80
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosed Parkinson patients with known genetic characteristics

        Exclusion Criteria:

          -  patients unable to understand and sign an informed consent

          -  minors

          -  patients in medical condition that does not allow them to stay still during the
             examination
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Einat Even-Sapir, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv Sourasky Medical Center, Tel Aviv, Israel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Einat Even-sapir, PhD, MD</last_name>
    <phone>972-3-6974444</phone>
    <phone_ext>3536</phone_ext>
    <email>evensap@tasmc.health.gov.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ayelet Kurzband, BA</last_name>
    <phone>972-3-6974444</phone>
    <phone_ext>3536</phone_ext>
    <email>ayeletk@tasmc.health.gov.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Nuclear Medicine, Tel Aviv Sourasky Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Einat Even-Sapir, MD, PhD</last_name>
      <phone>972-3-6974444</phone>
      <phone_ext>3536</phone_ext>
      <email>Evensap@tasmc.health.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Ayelet Kurzband, BA</last_name>
      <phone>972-3-6974444</phone>
      <phone_ext>3536</phone_ext>
      <email>ayeletk@tasmc.health.gov.il</email>
    </contact_backup>
    <investigator>
      <last_name>Hedva Lerman, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nir Giladi, PhD, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anat Milerman</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Volkow ND, Ding YS, Fowler JS, Wang GJ, Logan J, Gatley SJ, Hitzemann R, Smith G, Fields SD, Gur R. Dopamine transporters decrease with age. J Nucl Med. 1996 Apr;37(4):554-9.</citation>
    <PMID>8691238</PMID>
  </reference>
  <reference>
    <citation>Huang Y, Cheung L, Rowe D, Halliday G. Genetic contributions to Parkinson's disease. Brain Res Brain Res Rev. 2004 Aug;46(1):44-70. Review.</citation>
    <PMID>15297154</PMID>
  </reference>
  <reference>
    <citation>Vila M, Przedborski S. Genetic clues to the pathogenesis of Parkinson's disease. Nat Med. 2004 Jul;10 Suppl:S58-62. Review.</citation>
    <PMID>15272270</PMID>
  </reference>
  <reference>
    <citation>von Bohlen und Halbach O, Schober A, Krieglstein K. Genes, proteins, and neurotoxins involved in Parkinson's disease. Prog Neurobiol. 2004 Jun;73(3):151-77. Review.</citation>
    <PMID>15236834</PMID>
  </reference>
  <reference>
    <citation>Farrer M, Stone J, Mata IF, Lincoln S, Kachergus J, Hulihan M, Strain KJ, Maraganore DM. LRRK2 mutations in Parkinson disease. Neurology. 2005 Sep 13;65(5):738-40.</citation>
    <PMID>16157908</PMID>
  </reference>
  <reference>
    <citation>Orr-Urtreger A, Shifrin C, Rozovski U, Rosner S, Bercovich D, Gurevich T, Yagev-More H, Bar-Shira A, Giladi N. The LRRK2 G2019S mutation in Ashkenazi Jews with Parkinson disease: is there a gender effect? Neurology. 2007 Oct 16;69(16):1595-602.</citation>
    <PMID>17938369</PMID>
  </reference>
  <reference>
    <citation>Herholz K, Heiss WD. Positron emission tomography in clinical neurology. Mol Imaging Biol. 2004 Jul-Aug;6(4):239-69. Review.</citation>
    <PMID>15262239</PMID>
  </reference>
  <reference>
    <citation>Pavese N, Brooks DJ. Imaging neurodegeneration in Parkinson's disease. Biochim Biophys Acta. 2009 Jul;1792(7):722-9. doi: 10.1016/j.bbadis.2008.10.003. Epub 2008 Oct 17. Review.</citation>
    <PMID>18992326</PMID>
  </reference>
  <reference>
    <citation>Ozelius LJ, Senthil G, Saunders-Pullman R, Ohmann E, Deligtisch A, Tagliati M, Hunt AL, Klein C, Henick B, Hailpern SM, Lipton RB, Soto-Valencia J, Risch N, Bressman SB. LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N Engl J Med. 2006 Jan 26;354(4):424-5.</citation>
    <PMID>16436782</PMID>
  </reference>
  <reference>
    <citation>Thaler A, Ash E, Gan-Or Z, Orr-Urtreger A, Giladi N. The LRRK2 G2019S mutation as the cause of Parkinson's disease in Ashkenazi Jews. J Neural Transm (Vienna). 2009 Nov;116(11):1473-82. doi: 10.1007/s00702-009-0303-0. Review.</citation>
    <PMID>19756366</PMID>
  </reference>
  <reference>
    <citation>Hassin-Baer S, Laitman Y, Azizi E, Molchadski I, Galore-Haskel G, Barak F, Cohen OS, Friedman E. The leucine rich repeat kinase 2 (LRRK2) G2019S substitution mutation. Association with Parkinson disease, malignant melanoma and prevalence in ethnic groups in Israel. J Neurol. 2009 Mar;256(3):483-7. doi: 10.1007/s00415-009-0117-x. Epub 2009 Mar 24.</citation>
    <PMID>19412725</PMID>
  </reference>
  <reference>
    <citation>Gan-Or Z, Giladi N, Rozovski U, Shifrin C, Rosner S, Gurevich T, Bar-Shira A, Orr-Urtreger A. Genotype-phenotype correlations between GBA mutations and Parkinson disease risk and onset. Neurology. 2008 Jun 10;70(24):2277-83. doi: 10.1212/01.wnl.0000304039.11891.29. Epub 2008 Apr 23.</citation>
    <PMID>18434642</PMID>
  </reference>
  <verification_date>March 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2010</study_first_submitted>
  <study_first_submitted_qc>March 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2010</study_first_posted>
  <last_update_submitted>March 17, 2010</last_update_submitted>
  <last_update_submitted_qc>March 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 18, 2010</last_update_posted>
  <responsible_party>
    <name_title>Einat Even-Sapir MD, PhD. Head, Dept of Nuclear Medicine</name_title>
    <organization>Tel Aviv Sourasky Medical Center</organization>
  </responsible_party>
  <keyword>parkinson</keyword>
  <keyword>fdg pet-ct</keyword>
  <keyword>i123 dat scan</keyword>
  <keyword>LRRK2</keyword>
  <keyword>GBA</keyword>
  <keyword>parkinson patients with known genetic characteristic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Parkinson Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

